TY - JOUR
T1 - Quantitative imaging to assess tumor response to therapy
T2 - common themes of measurement, truth data, and error sources
AU - Meyer, Charles R.
AU - Armato III, Samuel G.
AU - Fenimore, Charles P.
AU - McLennan, Geoffrey
AU - Bidaut, Luc M.
AU - Barboriak, Daniel P.
AU - Gavrielides, Marios A.
AU - Jackson, Edward F.
AU - McNitt-Gray, Michael F.
AU - Kinahan, Paul E.
AU - Petrick, Nicholas
AU - Zhao, Binsheng
PY - 2009/1/1
Y1 - 2009/1/1
N2 - RATIONALE: Early detection of tumor response to therapy is a key goal. Finding measurement algorithms capable of early detection of tumor response could individualize therapy treatment as well as reduce the cost of bringing new drugs to market. On an individual basis, the urgency arises from the desire to prevent continued treatment of the patient with a high-cost and/or high-risk regimen with no demonstrated individual benefit and rapidly switch the patient to an alternative efficacious therapy for that patient. In the context of bringing new drugs to market, such algorithms could demonstrate efficacy in much smaller populations, which would allow phase 3 trials to achieve statistically significant decisions with fewer subjects in shorter trials. MATERIALS AND METHODS: This consensus-based article describes multiple, imagemodality- independentmeans to assess the relative performance of algorithms for measuring tumor change in response to therapy. In this setting, we describe specifically the example of measurement of tumor volume change from anatomic imaging as well as provide an overview of other promising generic analytic methods that can be used to assess change in heterogeneous tumors. To support assessment of the relative performance of algorithms for measuring small tumor change, data sources of truth are required. RESULTS: Very short interval clinical imaging examinations and phantom scans provide known truth for comparative evaluation of algorithms. CONCLUSIONS: For a given category ofmeasurementmethods, the algorithmthat has the smallest measurement noise and least bias on average will perform best in early detection of true tumor change.
AB - RATIONALE: Early detection of tumor response to therapy is a key goal. Finding measurement algorithms capable of early detection of tumor response could individualize therapy treatment as well as reduce the cost of bringing new drugs to market. On an individual basis, the urgency arises from the desire to prevent continued treatment of the patient with a high-cost and/or high-risk regimen with no demonstrated individual benefit and rapidly switch the patient to an alternative efficacious therapy for that patient. In the context of bringing new drugs to market, such algorithms could demonstrate efficacy in much smaller populations, which would allow phase 3 trials to achieve statistically significant decisions with fewer subjects in shorter trials. MATERIALS AND METHODS: This consensus-based article describes multiple, imagemodality- independentmeans to assess the relative performance of algorithms for measuring tumor change in response to therapy. In this setting, we describe specifically the example of measurement of tumor volume change from anatomic imaging as well as provide an overview of other promising generic analytic methods that can be used to assess change in heterogeneous tumors. To support assessment of the relative performance of algorithms for measuring small tumor change, data sources of truth are required. RESULTS: Very short interval clinical imaging examinations and phantom scans provide known truth for comparative evaluation of algorithms. CONCLUSIONS: For a given category ofmeasurementmethods, the algorithmthat has the smallest measurement noise and least bias on average will perform best in early detection of true tumor change.
UR - http://www.scopus.com/inward/record.url?scp=77953450740&partnerID=8YFLogxK
U2 - 10.1593/tlo.09208
DO - 10.1593/tlo.09208
M3 - Article
AN - SCOPUS:77953450740
SN - 1944-7124
VL - 2
SP - 198
EP - 210
JO - Translational Oncology
JF - Translational Oncology
IS - 4
ER -